$GMED

ZARRILLI STEPHEN T sold $2.2M of GMED

ZARRILLI STEPHEN T sold 25,000 shares of GLOBUS MEDICAL INC (GMED) at $87.04 ($2.18M total) on 2026-08-18.

Original reporting
SEC EDGAR · ZARRILLI STEPHEN T
Published Aug 19, 2026, 9:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GMED
Neutral
medium confidence
Mentioned
$GMED
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GMEDNeutralLow
01

Why it matters

The sale reduces insider ownership to zero, which may affect perception of insider alignment with shareholders.

02

Market read

Insider sell of $2.2M may cause slight price dip but unlikely to trigger major market moves.

03

What to watch

Potential tax planning or personal liquidity needs may drive the transaction.

Relevance 6/10Novelty 7/10Timing: filing disclosed today

Background

Form 4 filings disclose insider transactions; a director's complete exit is noteworthy.

Company-level read

Ticker impact

$GMEDNeutralMedium confidence
Context

Director Stephen Zarrilli sold 25,000 shares for $2.18M, reducing his stake to zero.

Expected impact

Potential slight downward pressure, likely within normal volatility range.

Evidence & confidence

A $2.2M sale by a director is notable but not large enough to drive a significant move; market may view it as routine portfolio rebalancing.

Market effects

Minimal impact on the medical device sector.

No broader regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be unrelated to company outlook; insiders often diversify holdings.

Key entities

  • Globus Medical Inc

    Medical device manufacturer listed on NASDAQ (GMED).

  • Stephen Zarrilli

    Director of Globus Medical who sold his entire stake.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GMEDMed

GMED Looks 14.2% Undervalued on GF Value™

Globus Medical Inc (GMED) acquired Higgs Boson Health to enhance its digital capabilities with AI-driven analytics. GMED's stock is 14.2% undervalued at $83.10 vs. GF Value™ of $96.83, with a GF Score™ of 94. Insider selling totals $15.9M, while 8 gurus hold the stock. GMED's P/E ratio is 21.25x, below its 5-year median of 40.78x.

$GMEDMedAI 8/10

Globus Medical Q2 2026 Earnings: Revenue Beats $789.6 Million

Globus Medical (NYSE: GMED) reported Q2 2026 revenue of $789.6 million, up 5.9% year over year, and GAAP EPS of $1.10. Non-GAAP EPS was a record $1.34, beating consensus, and non-GAAP net income rose to $184.3 million. The company reaffirmed 2026 revenue guidance of $3.18–$3.22B and raised non-GAAP EPS guidance to $4.95–$5.05.

$GMEDMedAI 8/10

Globus Medical Q2 Earnings Call Highlights

Globus Medical (GMED) reported Q2 results on an earnings call. International spine revenue rose 12% constant-currency. Trauma revenue grew 31% YoY and 18% sequentially. Enabling Technologies revenue fell 26% YoY to $26.1M, while Excelsius placements rose. Nevro revenue declined 14.3% YoY. GAAP gross margin was 66.8%. GMED raised 2026 non-GAAP EPS to $4.95-$5.05 and reaffirmed revenue guidance of $3.18-$3.22B.